

REMARKS

Reconsideration and allowance of the application are respectfully requested in light of the foregoing amendments and the following remarks.

Claims 1 and 58-62 are pending in the application. Claims 1 and 58-61 are canceled herein without prejudice or disclaimer. Claim 62 is amended as an independent claim using Markush-type language. Entry thereof is respectfully requested.

Claims 1 and 58-61 were rejected under 35 U.S.C. §112, first paragraph, for indefiniteness. Cancellation of these claims hereby renders this rejection moot. This is not to be construed as an acquiescence to any alleged merits of the rejection. Instead, this action is taken to expedite allowance of the application.

Claim 62 was objected to, with the Office indicating that it contained otherwise allowable subject matter. In response, this claim has been re-written in independent format. The Markush-type language sets forth the individual compounds recited in this claim. It is respectfully requested that the objection to claim 62 be removed, and this claim be allowed to grant.

The application is believed to be in proper condition for allowance, and prompt, favorable action thereon is earnestly solicited. Should Examiner Balasubramanian feel that any other point requires consideration, then he is cordially invited to contact the undersigned.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

/john f levis/  
John F. Levis  
Attorney for Applicants  
Reg. No. 34,210  
Phone: 203-677-3782  
Date: August 23, 2007